Transforming Growth Factor-beta Regulates DNA Binding Activity of Transcription Factor Fli1 by P300/CREB-binding Protein-associated Factor-dependent Acetylation
Overview
Affiliations
Fli1, a member of Ets transcriptional factors, has been shown to be a negative regulator of collagen gene expression in dermal fibroblasts. Although Fli1 down-regulation is implicated in pathological matrix remodeling such as cutaneous fibrosis in scleroderma, very little is known about the post-translational mechanisms regulating Fli1 function. The aim of this study was to investigate the role of acetylation, one of the main post-translational regulatory mechanisms, in regulating Fli1 activity. We initially demonstrated that Fli1 is acetylated by transforming growth factor (TGF)-beta1 in dermal fibroblasts. An in vivo acetylation assay using 293T cells revealed that Fli1 is mainly acetylated by the histone acetyltransferase activity of p300/CBP-associated factor (PCAF) at lysine 380. Acetylation of Fli1 resulted in a decreased stability of Fli1 protein. More importantly, reduced binding of acetylated Fli1 to the human alpha2(I) collagen (COL1A2) promoter was observed in DNA affinity precipitation and chromatin immunoprecipitation. Conversely, a Fli1 K380R mutant that is resistant to acetylation by PCAF showed increased DNA binding ability. Furthermore, PCAF overexpression reversed the inhibitory effect of Fli1 on TGF-beta1-mediated COL1A2 promoter activity. In contrast, the Fli1 K380R mutant had a greater inhibitory effect on TGF-beta1-induced COL1A2 promoter activity than wild-type Fli1, and PCAF failed to reverse this effect. These results indicate that PCAF-dependent acetylation of lysine 380 abrogates repressor function of Fli1 with respect to collagen gene expression. Furthermore, these data strongly suggest that the TGF-beta-dependent acetylation of Fli1 may represent the principal mechanism responsible for the TGF-beta-induced dissociation of Fli1 from the collagen promoter.
Role of the transcription factor Fli-1 on the CXCL10/CXCR3 Axis.
Wang X, Richard M, Caldwell T, Sundararaj K, Sato S, Nowling T Front Immunol. 2023; 14:1219279.
PMID: 37790939 PMC: 10543418. DOI: 10.3389/fimmu.2023.1219279.
Fli1 and Tissue Fibrosis in Various Diseases.
Mikhailova E, Romanova I, Bagrov A, Agalakova N Int J Mol Sci. 2023; 24(3).
PMID: 36768203 PMC: 9915382. DOI: 10.3390/ijms24031881.
Histone modification of endothelial-mesenchymal transition in cardiovascular diseases.
Jun Q, Youhong L, Yuan Z, Xi Y, Wang B, Xinyi S Front Cardiovasc Med. 2022; 9:1022988.
PMID: 36568553 PMC: 9768231. DOI: 10.3389/fcvm.2022.1022988.
A broad look into the future of systemic sclerosis.
Riemekasten G, Distler J Ther Adv Musculoskelet Dis. 2022; 14:1759720X221109404.
PMID: 35966183 PMC: 9373175. DOI: 10.1177/1759720X221109404.
Therapeutic molecular targets of SSc-ILD.
Zhang Y, Distler J J Scleroderma Relat Disord. 2022; 5(2 Suppl):17-30.
PMID: 35382225 PMC: 8922571. DOI: 10.1177/2397198319899013.